NO801843L - Nye kinazolinderivater og farmasoeytiske preparater - Google Patents
Nye kinazolinderivater og farmasoeytiske preparaterInfo
- Publication number
- NO801843L NO801843L NO801843A NO801843A NO801843L NO 801843 L NO801843 L NO 801843L NO 801843 A NO801843 A NO 801843A NO 801843 A NO801843 A NO 801843A NO 801843 L NO801843 L NO 801843L
- Authority
- NO
- Norway
- Prior art keywords
- formula
- compound
- compounds
- imidazo
- tautomers
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 10
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 10
- 239000011707 mineral Substances 0.000 claims description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 8
- 150000007513 acids Chemical class 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- IASFSCWLFJGXQL-UHFFFAOYSA-N 7-bromo-3,6-dimethyl-5,10-dihydro-3h-imidazo[2,1-b]quinazolin-2-one Chemical compound C1C2=C(C)C(Br)=CC=C2N=C2N1C(C)C(=O)N2 IASFSCWLFJGXQL-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 2
- IASFSCWLFJGXQL-SSDOTTSWSA-N (3r)-7-bromo-3,6-dimethyl-5,10-dihydro-3h-imidazo[2,1-b]quinazolin-2-one Chemical compound C1=CC(Br)=C(C)C2=C1NC1=NC(=O)[C@@H](C)N1C2 IASFSCWLFJGXQL-SSDOTTSWSA-N 0.000 claims 1
- 101000798092 Mus musculus tRNA (cytosine(38)-C(5))-methyltransferase Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- 229950006790 adenosine phosphate Drugs 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- LRJUDHXAKVINPW-MRVPVSSYSA-N (3R)-3,6-dimethyl-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one Chemical compound C1C2=C(C)C=CC=C2N=C2N1[C@H](C)C(=O)N2 LRJUDHXAKVINPW-MRVPVSSYSA-N 0.000 description 2
- -1 6-chloro-1,5-dihydro-7-methoxy-3-methyl-imidazo[2,1-b]quinazolin-2(3H)-one Chemical compound 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- MGYXDYAXFVTSMG-OGFXRTJISA-N (3R)-7-bromo-3,6-dimethyl-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one hydrobromide Chemical compound Br.C1C2=C(C)C(Br)=CC=C2N=C2N1[C@H](C)C(=O)N2 MGYXDYAXFVTSMG-OGFXRTJISA-N 0.000 description 1
- GVVWMNCMCBUZFF-RXMQYKEDSA-N (3R)-7-bromo-6-chloro-3-methyl-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one Chemical compound C1C2=C(Cl)C(Br)=CC=C2N=C2N1[C@H](C)C(=O)N2 GVVWMNCMCBUZFF-RXMQYKEDSA-N 0.000 description 1
- FVHAWXWFPBPFOS-UHFFFAOYSA-N 1,2-dimethyl-3-nitrobenzene Chemical group CC1=CC=CC([N+]([O-])=O)=C1C FVHAWXWFPBPFOS-UHFFFAOYSA-N 0.000 description 1
- KPWVALMTRXELOS-UHFFFAOYSA-N 1-(bromomethyl)-2-methyl-3-nitrobenzene Chemical compound CC1=C(CBr)C=CC=C1[N+]([O-])=O KPWVALMTRXELOS-UHFFFAOYSA-N 0.000 description 1
- MVLKTVRKDHDFOJ-UHFFFAOYSA-N 2-(bromomethyl)-1-methyl-3-nitrobenzene Chemical compound CC1=CC=CC([N+]([O-])=O)=C1CBr MVLKTVRKDHDFOJ-UHFFFAOYSA-N 0.000 description 1
- PYBVRWQLJHXDMG-UHFFFAOYSA-N 2-chloro-1-methoxy-3-methyl-4-nitrobenzene Chemical compound COC1=CC=C([N+]([O-])=O)C(C)=C1Cl PYBVRWQLJHXDMG-UHFFFAOYSA-N 0.000 description 1
- YQHHUFAUAXOCKF-UHFFFAOYSA-N 3-(bromomethyl)-2-chloro-1-methoxy-4-nitrobenzene Chemical compound COC1=CC=C([N+]([O-])=O)C(CBr)=C1Cl YQHHUFAUAXOCKF-UHFFFAOYSA-N 0.000 description 1
- GVVWMNCMCBUZFF-UHFFFAOYSA-N 7-bromo-6-chloro-3-methyl-5,10-dihydro-3h-imidazo[2,1-b]quinazolin-2-one Chemical compound C1=CC(Br)=C(Cl)C2=C1NC1=NC(=O)C(C)N1C2 GVVWMNCMCBUZFF-UHFFFAOYSA-N 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Chemical class [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- MMSUMQDVUIHESI-MRVPVSSYSA-N ethyl (2R)-2-[(2-chloro-3-methoxy-6-nitrophenyl)methylamino]propanoate Chemical compound C(C)OC([C@H](NCC1=C(C=CC(=C1Cl)OC)[N+](=O)[O-])C)=O MMSUMQDVUIHESI-MRVPVSSYSA-N 0.000 description 1
- ZJYZQVSCSFKDPV-SNVBAGLBSA-N ethyl (2r)-2-[(2-amino-3-methylphenyl)methylamino]propanoate Chemical compound CCOC(=O)[C@@H](C)NCC1=CC=CC(C)=C1N ZJYZQVSCSFKDPV-SNVBAGLBSA-N 0.000 description 1
- OAXCTGQHMMFUIZ-SNVBAGLBSA-N ethyl (2r)-2-[(2-methyl-3-nitrophenyl)methylamino]propanoate Chemical compound CCOC(=O)[C@@H](C)NCC1=CC=CC([N+]([O-])=O)=C1C OAXCTGQHMMFUIZ-SNVBAGLBSA-N 0.000 description 1
- JCXLZWMDXJFOOI-PGMHMLKASA-N ethyl (2r)-2-aminopropanoate;hydrochloride Chemical compound Cl.CCOC(=O)[C@@H](C)N JCXLZWMDXJFOOI-PGMHMLKASA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/050,395 US4256748A (en) | 1977-07-25 | 1979-06-20 | Imidazo[2,1-b]quinazolin-2(3H)-ones and pharmaceutical compositions for treatment and prophylaxis of cardiac insufficiency and cardiac failure |
| CH360080 | 1980-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO801843L true NO801843L (no) | 1980-12-22 |
Family
ID=25693404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO801843A NO801843L (no) | 1979-06-20 | 1980-06-19 | Nye kinazolinderivater og farmasoeytiske preparater |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0021338B1 (es) |
| AU (1) | AU538119B2 (es) |
| CA (1) | CA1131631A (es) |
| DE (1) | DE3065273D1 (es) |
| DK (1) | DK259380A (es) |
| ES (3) | ES8105321A1 (es) |
| FI (1) | FI66870C (es) |
| IL (1) | IL60325A (es) |
| MC (1) | MC1332A1 (es) |
| NO (1) | NO801843L (es) |
| NZ (1) | NZ194046A (es) |
| PH (1) | PH16369A (es) |
| PT (1) | PT71411B (es) |
| YU (1) | YU161580A (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0054180A3 (de) * | 1980-12-16 | 1982-12-01 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Verfahren zur Herstellung eines Imidazochinazolinonderivates |
| US4783467A (en) * | 1985-06-05 | 1988-11-08 | Pfizer Inc. | Tetrahydroimidazoquinazolinone inotropic agents |
| US6388073B1 (en) * | 2000-07-26 | 2002-05-14 | Shire Us Inc. | Method for the manufacture of anagrelide |
| US7700608B2 (en) | 2004-08-04 | 2010-04-20 | Shire Holdings Ag | Quinazoline derivatives and their use in the treatment of thrombocythemia |
| US8383637B2 (en) | 2004-08-06 | 2013-02-26 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
| US8436006B2 (en) | 2004-08-06 | 2013-05-07 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
| US8426429B2 (en) | 2004-08-06 | 2013-04-23 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
| US7910597B2 (en) | 2006-11-28 | 2011-03-22 | Shire Llc | Substituted quinazolines |
| US8304420B2 (en) | 2006-11-28 | 2012-11-06 | Shire Llc | Substituted quinazolines for reducing platelet count |
| GB0623750D0 (en) | 2006-11-28 | 2007-01-10 | Shire Llc | Substituted quinazolines |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE794964A (fr) * | 1972-02-04 | 1973-08-02 | Bristol Myers Co | Nouveaux agents hypotenseurs et procede pour les preparer |
| US3932407A (en) * | 1973-11-19 | 1976-01-13 | Bristol-Myers Company | Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones |
| US3988340A (en) * | 1975-01-23 | 1976-10-26 | Bristol-Myers Company | 6-Alkoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones and 7-alkoxymethyl-6-[H]-1,2,3,4-tetrahydropyrimido[2,1-b]quinazolin-2-ones |
| NL7807507A (nl) * | 1977-07-25 | 1979-01-29 | Hoffmann La Roche | Tricyclische verbindingen. |
| US4146718A (en) * | 1978-04-10 | 1979-03-27 | Bristol-Myers Company | Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides |
-
1980
- 1980-06-06 CA CA353,659A patent/CA1131631A/en not_active Expired
- 1980-06-13 NZ NZ194046A patent/NZ194046A/xx unknown
- 1980-06-13 FI FI801910A patent/FI66870C/fi not_active IP Right Cessation
- 1980-06-16 IL IL60325A patent/IL60325A/xx unknown
- 1980-06-17 DK DK259380A patent/DK259380A/da not_active Application Discontinuation
- 1980-06-17 AU AU59339/80A patent/AU538119B2/en not_active Ceased
- 1980-06-18 MC MC801454A patent/MC1332A1/xx unknown
- 1980-06-18 PT PT71411A patent/PT71411B/pt unknown
- 1980-06-18 DE DE8080103396T patent/DE3065273D1/de not_active Expired
- 1980-06-18 EP EP80103396A patent/EP0021338B1/de not_active Expired
- 1980-06-19 ES ES492573A patent/ES8105321A1/es not_active Expired
- 1980-06-19 NO NO801843A patent/NO801843L/no unknown
- 1980-06-19 YU YU01615/80A patent/YU161580A/xx unknown
- 1980-06-20 PH PH24171A patent/PH16369A/en unknown
-
1981
- 1981-02-16 ES ES499454A patent/ES8201164A1/es not_active Expired
- 1981-02-16 ES ES499455A patent/ES8206524A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| PT71411A (en) | 1980-07-01 |
| ES499455A0 (es) | 1982-08-16 |
| NZ194046A (en) | 1982-05-25 |
| PT71411B (en) | 1981-12-11 |
| ES492573A0 (es) | 1981-06-01 |
| EP0021338A1 (de) | 1981-01-07 |
| AU538119B2 (en) | 1984-08-02 |
| EP0021338B1 (de) | 1983-10-12 |
| ES8206524A1 (es) | 1982-08-16 |
| FI66870B (fi) | 1984-08-31 |
| AU5933980A (en) | 1981-01-08 |
| CA1131631A (en) | 1982-09-14 |
| FI66870C (fi) | 1984-12-10 |
| ES499454A0 (es) | 1981-12-01 |
| MC1332A1 (fr) | 1981-04-21 |
| ES8201164A1 (es) | 1981-12-01 |
| ES8105321A1 (es) | 1981-06-01 |
| YU161580A (en) | 1983-04-30 |
| DK259380A (da) | 1980-12-21 |
| DE3065273D1 (de) | 1983-11-17 |
| PH16369A (en) | 1983-09-14 |
| FI801910A (fi) | 1980-12-21 |
| IL60325A0 (en) | 1980-09-16 |
| IL60325A (en) | 1983-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4256748A (en) | Imidazo[2,1-b]quinazolin-2(3H)-ones and pharmaceutical compositions for treatment and prophylaxis of cardiac insufficiency and cardiac failure | |
| DE69233401T2 (de) | Verbrückte zyklische polyamine mit anti-hiv wirkung | |
| DE3614132A1 (de) | 1,3-dihydro-2h-imidazo(4,5-b)chinolin-2-one, verfahren zu deren herstellung und diese verbindungen enthaltende, pharmazeutische mittel | |
| PT93823B (pt) | Processo para a preparacao de derivados de pirimidina e de composicoes farmaceuticas que os contem | |
| PL136217B1 (en) | Method of obtaining novel derivatives of 4-amino-6,7-dimetoxy-2-piprazinoquinazoline | |
| NO159272B (no) | Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive dihydropyridiner. | |
| DD297819A5 (de) | Verfahren zur herstellung von 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidinderivaten | |
| NO801843L (no) | Nye kinazolinderivater og farmasoeytiske preparater | |
| HU187357B (en) | Process for producing isoquinoline derivatives | |
| JPS6322082A (ja) | １―（ヒドロキシスチリル）―５ｈ―２，３―ベンゾジアゼピン誘導体およびその製造方法、並びに前記誘導体を含む薬剤 | |
| US6103724A (en) | 2-methoxyphenylpiperazine derivatives | |
| US4617393A (en) | 5-substituted-6-aminopyrimidines, composition and uses as cardiotonic agents for increasing cardiac contractility | |
| KR840000794B1 (ko) | 퀴나졸린 유도체의 제조방법 | |
| NO161220B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktivt 7-piperidin-1,2,3,5-tetrahydroimidazo-(2,1-b)-kinazolin-2-on. | |
| EP0124893A2 (de) | Neue Pyrimidonderivate | |
| US4088647A (en) | Pyrazino (1,2,3-ab)-β-carboline derivatives and salts thereof and method of preparing same | |
| NO812766L (no) | Imidazokinazolinderivater. | |
| FI63568C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara i 7-staellning substituerade 8-aminometylisoflavonderivat | |
| JP6301474B2 (ja) | 癌および炎症性疾患を処置するための新規化合物 | |
| WO1992015310A1 (de) | Verwendung von tricyclischen isoindolinonen als antivirale arzneimittel, sowie neue optisch aktive isoindolinone | |
| PL79758B1 (en) | Pharmaceutical compositions containing a tricyclic heterocyclic amide of a diallylamino-alkanoic acid [us3749785a] | |
| EP0180833B1 (de) | 4-Oxo-pyrido[2,3]pyrimidin-Derivate, Verfahren zur deren Herstellung und diese ethaltende Arzneimittel | |
| US4612317A (en) | Tetrahydro-β-carboline dithioic acid derivatives and treatment of liver diseases | |
| NO761537L (es) | ||
| NO150280B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive 9-aminopyrido(1,2-a)pyrimidinderivater |